8-K: Bruker Q3 2025 Revenue Dips, Lowers FY Guidance

Bruker Corporation reported a slight revenue decrease and a GAAP loss in Q3 2025, leading to a revised downward full-year 2025 financial outlook, despite better-than-expected non-GAAP performance.

Summary

• Q3 2025 revenues were $860.5 million, a decrease of 0.5% year-over-year (yoy) and a 4.5% organic decline.
• Q3 2025 GAAP diluted loss per share was $(0.41), compared to diluted earnings per share of $0.27 in Q3 2024.
• Q3 2025 non-GAAP diluted earnings per share (EPS) was $0.45, down from $0.60 in Q3 2024.
• The company updated its FY2025 revenue guidance to $3.41 to $3.44 billion, representing 1% to 2% reported growth yoy, but an organic decline of 4% to 5%.
• Updated FY2025 non-GAAP EPS guidance is $1.85 to $1.90, down from FY2024 non-GAAP EPS of $2.41.
• Q3 2025 GAAP operating loss was $51.8 million, significantly down from GAAP operating income of $68.1 million in Q3 2024, primarily due to $119.4 million in non-cash impairment charges and $34.5 million in restructuring charges.
• Q3 2025 non-GAAP operating income was $105.9 million, with a non-GAAP operating margin of 12.3%, compared to $129.1 million and 14.9% respectively in Q3 2024.
• For the first nine months of 2025, revenues were $2.46 billion, an increase of 3.0% yoy, but with a 3.1% organic decline.
• First nine months 2025 GAAP diluted loss per share was $(0.25), compared to GAAP diluted earnings per share of $0.67 in the first nine months of 2024.
• First nine months 2025 non-GAAP diluted EPS was $1.23, compared to $1.65 in the first nine months of 2024.

Sentiment

Score: 4

Explanation: While the company reported better-than-expected non-GAAP performance for Q3 and positive bookings trends, the significant GAAP loss, substantial impairment charges, and a downward revision of full-year guidance indicate underlying challenges. The positive outlook for FY2026 based on cost savings provides some optimism, but current performance is weak.

Positives

• Mid-single digit percentage organic bookings growth year-over-year in Q3 2025.
• Scientific Instruments segment achieved a book-to-bill ratio greater than 1.0 in Q3 2025.
• Strength in bookings observed in the academic/government market segment in Q3 2025.
• Improving orders noted in biopharma and applied markets during Q3 2025.
• Innovative spatial biology, proteomics, and multiomics solutions are being well received by biopharma and academic customers.
• Q3 2025 non-GAAP financial performance was better than expected and showed a meaningful sequential step-up from Q2 2025.
• Major cost-savings initiatives for FY2026 are progressing well towards the high end of the $100 to $120 million targets, expected to deliver significant operating margin expansion and EPS growth.
• Bruker Energy & Supercon Technologies (BEST) revenues increased 7.4% yoy (6.9% organically) in Q3 2025.
• Foreign currency translation had a favorable impact on revenue, contributing 2.9% in Q3 2025 and 1.6% for the first nine months of 2025.

Negatives

• Q3 2025 revenues decreased 0.5% year-over-year and 4.5% organically.
• Reported a Q3 2025 GAAP diluted loss per share of $(0.41), a significant decline from diluted earnings per share of $0.27 in Q3 2024.
• Q3 2025 GAAP operating loss was $51.8 million, compared to GAAP operating income of $68.1 million in Q3 2024.
• GAAP results were heavily impacted by $119.4 million in non-cash impairment charges related to goodwill and intangible assets, and $34.5 million in restructuring charges in Q3 2025.
• Non-GAAP operating income and margin decreased in Q3 2025 and the first nine months of 2025.
• Non-GAAP diluted EPS decreased in Q3 2025 ($0.45 vs. $0.60) and the first nine months of 2025 ($1.23 vs. $1.65).
• Lowered FY2025 guidance for both revenue and non-GAAP EPS due to previous market weakness and EPS dilution from a higher share count.
• Weaker academic and research instruments demand in the first half of 2025 primarily contributed to the year-over-year decline in Q3 revenues and earnings.
• Bruker Scientific Instruments (BSI) revenues decreased 1.5% yoy (5.4% organically) in Q3 2025.
• BEST revenues decreased 5.5% yoy (5.5% organically) for the first nine months of 2025.
• Net cash used in operating activities for Q3 2025 was $(33.2) million, compared to $38.4 million provided in Q3 2024.
• Net cash used in operating activities for the first nine months of 2025 was $(95.7) million, compared to $61.3 million provided in the first nine months of 2024.
• Free cash flow was negative for both Q3 2025 ($(54.1) million) and the first nine months of 2025 ($(163.9) million).

Risks

• The length and severity of any recession and its impact on global economic conditions.
• Impact of supply chain challenges, including inflationary pressures.
• Impact of geopolitical tensions and any sanctions, including reduction in natural gas exports from Russia, market disruptions, and higher prices for and reduced availability of key metals.
• The conflict in Israel, Palestine, and surrounding areas and the possible expansion of such conflicts and potential geopolitical consequences.
• Ongoing tensions between the United States and China, tariff and trade policy changes, and the increasing potential of conflict involving countries in Asia critical to supply chain operations, such as Taiwan and China.
• Continued volatility in the capital markets and the impact of increased interest rates.
• Challenges related to the integration and assumption of liabilities of acquired businesses, including PhenomeX, ELITech, Chemspeed, and NanoString.
• Effectiveness and impact of restructuring and cost-control initiatives.
• Risks associated with changing technologies, product development, and market acceptance of products.
• Fluctuations in the cost and pricing of products, and challenges in manufacturing and outsourcing.
• Intense competition within the industry.
• Dependence on collaborative partners, key suppliers, and third-party distributors.
• Impact of capital spending and government funding policies.
• Changes in governmental regulations.
• Protection of intellectual property rights and potential litigation.
• Exposure to foreign currency fluctuations and the impact of foreign currency exchange rates.
• Ability to service debt obligations and fund anticipated cash needs.
• The effect of a concentrated ownership of common stock.
• Loss of key personnel.
• Decisions regarding the payment of future dividends.

Future Outlook

Bruker updated its FY2025 revenue guidance to $3.41 to $3.44 billion, representing 1% to 2% reported growth but an organic decline of 4% to 5%. Non-GAAP EPS guidance was lowered to $1.85 to $1.90. For FY2026, the company anticipates significant operating margin expansion and EPS growth driven by major cost-savings initiatives targeting $100 to $120 million.

Management Comments

• "In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0."
• "For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders."
• "Our innovative spatial biology, proteomics and multiomics solutions launched at AGBT and ASMS are being well received by our biopharma and academic customers and enhance our leadership in enabling tools for drug discovery and disease biology research in the post-genomic era."
• "As forecasted, our third quarter revenues and earnings were down year-over-year, primarily due to weaker academic and research instruments demand in the first half of 2025."
• "However, our Q3-25 non-GAAP financial performance was better than expected and represents a meaningful sequential step-up from Q2-25."
• "Nonetheless, due to previous market weakness and EPS dilution from higher share count, we are lowering our FY2025 guidance."
• "For FY2026, our major cost-savings initiatives are progressing well towards the high end of our $100 to $120 million cost-down targets and are expected to deliver significant operating margin expansion and EPS growth in 2026."

Industry Context

The company operates in the high-performance scientific instruments and analytical/diagnostic solutions market, focusing on post-genomic life science, molecular and cell biology research, applied and biopharma applications, microscopy, nanoanalysis, industrial, cleantech research, and next-gen semiconductor metrology. The reported weakness in academic and research instruments demand in the first half of 2025 suggests a broader market slowdown in these segments, potentially impacting other players reliant on government and academic funding. The strength in biopharma and applied markets, along with positive reception for new multiomics solutions, indicates a shift towards more targeted, high-growth areas within life sciences.

Legal Proceedings

• Acquisition-related litigation charges were reported as non-GAAP adjustments, totaling $4.1 million in Q3 2025 and $26.7 million for the first nine months of 2025.

Stakeholder Impact

• Shareholders face negative impacts from the GAAP loss, diluted EPS, and lowered guidance, but may see potential positives from future cost savings and EPS growth in FY2026.
• Employees may be affected by restructuring charges ($34.5 million in Q3 2025) and ongoing cost-saving initiatives, which could imply organizational changes.
• Customers benefit from continued innovation in spatial biology, proteomics, and multiomics solutions, enhancing the company's offerings.
• Creditors face risks related to the company's ability to service its substantial debt obligations ($1,984.2 million long-term debt as of Sep 30, 2025).
• Suppliers are exposed to risks related to the company's dependence on key suppliers, especially amidst supply chain challenges and geopolitical tensions.

Next Steps

• Host a conference call and webcast on November 3, 2025, at 8:30 am Eastern Standard Time to discuss financial results and business outlook.
• Continue progressing major cost-savings initiatives for FY2026, targeting $100 to $120 million.

Key Dates

Recommendation

While the Q3 GAAP results were poor, marked by a significant loss and impairment charges, and the full-year guidance was lowered, there are some mitigating factors. The non-GAAP performance was better than expected sequentially, and the company reported positive organic bookings growth and a book-to-bill ratio greater than 1.0 in its Scientific Instruments segment. Furthermore, management has outlined substantial cost-saving initiatives for FY2026, which are expected to drive significant operating margin expansion and EPS growth. Given the mixed signals – current weakness offset by future strategic initiatives and some positive operational trends – a 'Hold' recommendation is appropriate for a seasoned investor to observe the execution of cost-saving measures and the realization of improved demand in academic/government and biopharma markets.

Keywords

Bruker, BRKR, financial results, Q3 2025, earnings, revenue, EPS, guidance, scientific instruments, biopharma, academic research, proteomics, multiomics, spatial biology, analytical solutions, life science, diagnostics, SEC filing, 8-K, impairment charges, restructuring